ERK-IN-3

CAS No. 2055597-12-9

ERK-IN-3 ( ASN007 free base )

Catalog No. M23920 CAS No. 2055597-12-9

ERK-IN-3 is a potent and orally active inhibitor of ERK. It inhibits ERK1/2 with low single-digit nM IC50 values. It can be used for the research of cancers driven by RAS mutations.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 71 In Stock
5MG 113 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    ERK-IN-3
  • Note
    Research use only, not for human use.
  • Brief Description
    ERK-IN-3 is a potent and orally active inhibitor of ERK. It inhibits ERK1/2 with low single-digit nM IC50 values. It can be used for the research of cancers driven by RAS mutations.
  • Description
    ERK-IN-3 is a potent and orally active inhibitor of ERK. It inhibits ERK1/2 with low single-digit nM IC50 values. It can be used for the research of cancers driven by RAS mutations.
  • Synonyms
    ASN007 free base
  • Pathway
    MAPK/ERK Signaling
  • Target
    ERK
  • Recptor
    ERK1;ERK2
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2055597-12-9
  • Formula Weight
    473.9
  • Molecular Formula
    C22H25ClFN7O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:250 mg/mL (527.50 mM; Need ultrasonic)
  • SMILES
    O=C(C1=CN(C2=NC(NC3CCOCC3)=NC=C2C)C=N1)N[C@@H](C4=CC(F)=CC(Cl)=C4)CN
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Sanjeeva PR, et, al. Abstract B150: ASN007, a novel oral ERK inhibitor, shows robust antitumor activity in RAS mutant cancer models. Molecular Cancer Therapeutics. 2018 Jan; 17(1).
molnova catalog
related products
  • Asperulosidic acid

    Asperulosidic acid has anti-tumor, anti-oxidant, and anti-inflammatory activities.ASPA is related to the inhibition of inflammatory cytokines (TNF-α, IL-6) and mediators via suppression of the NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways.

  • ERK5-IN-2

    ERK5-IN-2 is an orally active sub-micromolar selective ERK5 inhibitor with IC50s of 0.82 μM 3 μM for ERK5 and ERK5 MEF2D respectively.

  • FR 180204

    FR 180204 is a potent, selective, ATP-competitive ERK inhibitor with Ki of 0.31 and 0.14 uM for ERK1 and ERK2, respectively.